Clinical Trials Browser

OTHER × Lymphoma, B-Cell × Nivolumab × Clear all

NCT03017820 2026-06-10

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT06767956 2026-04-13

Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy

Phase 1/2 Withdrawn

Lymphoid

Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT03620578 2024-02-14

HO152

Phase 2 Active not recruiting

97 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT03704714 2022-08-15

Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

Phase 1/2 Suspended

30 enrolled

Lymphoid

Lymphoma, B-Cell

NCT03920631 2021-03-23

MicroBLITZ

Phase 1 Withdrawn

Lymphoid

Lymphoma, B-Cell